These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 37378526)

  • 1. An insight into structure-activity relationship of naturally derived biological macromolecules for the treatment of Alzheimer's disease: a review.
    Halder D; Das S; Joseph A
    J Biomol Struct Dyn; 2024 Aug; 42(12):6455-6471. PubMed ID: 37378526
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of multi-targeted bioactive natural molecules and their derivatives in the treatment of Alzheimer's disease: an insight into structure-activity relationship.
    Halder D; Das S; R S J; Joseph A
    J Biomol Struct Dyn; 2023 Dec; 41(20):11286-11323. PubMed ID: 36579430
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Potential therapeutic natural products against Alzheimer's disease with Reference of Acetylcholinesterase.
    Ahmed S; Khan ST; Zargaham MK; Khan AU; Khan S; Hussain A; Uddin J; Khan A; Al-Harrasi A
    Biomed Pharmacother; 2021 Jul; 139():111609. PubMed ID: 33915501
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Systematic Review on Donepezil-based Derivatives as Potential Cholinesterase Inhibitors for Alzheimer's Disease.
    Korabecny J; Spilovska K; Mezeiova E; Benek O; Juza R; Kaping D; Soukup O
    Curr Med Chem; 2019; 26(30):5625-5648. PubMed ID: 29768996
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Natural products as sources of new lead compounds for the treatment of Alzheimer's disease.
    Huang L; Su T; Li X
    Curr Top Med Chem; 2013; 13(15):1864-78. PubMed ID: 23931437
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effectiveness and cost-effectiveness of donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer's disease (review of Technology Appraisal No. 111): a systematic review and economic model.
    Bond M; Rogers G; Peters J; Anderson R; Hoyle M; Miners A; Moxham T; Davis S; Thokala P; Wailoo A; Jeffreys M; Hyde C
    Health Technol Assess; 2012; 16(21):1-470. PubMed ID: 22541366
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cholinesterase Inhibitors for Alzheimer's Disease: Multitargeting Strategy Based on Anti-Alzheimer's Drugs Repositioning.
    Kabir MT; Uddin MS; Begum MM; Thangapandiyan S; Rahman MS; Aleya L; Mathew B; Ahmed M; Barreto GE; Ashraf GM
    Curr Pharm Des; 2019; 25(33):3519-3535. PubMed ID: 31593530
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Features and outcomes of drugs for combination therapy as multi-targets strategy to combat Alzheimer's disease.
    Sahoo AK; Dandapat J; Dash UC; Kanhar S
    J Ethnopharmacol; 2018 Apr; 215():42-73. PubMed ID: 29248451
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dual-target compounds for Alzheimer's disease: Natural and synthetic AChE and BACE-1 dual-inhibitors and their structure-activity relationship (SAR).
    Ferreira JPS; Albuquerque HMT; Cardoso SM; Silva AMS; Silva VLM
    Eur J Med Chem; 2021 Oct; 221():113492. PubMed ID: 33984802
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Anti-Dementia Drugs (Anti-Alzheimer's Disease Drugs)].
    Yamada M
    Brain Nerve; 2023 May; 75(5):464-469. PubMed ID: 37194514
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A molecular approach in drug development for Alzheimer's disease.
    Agatonovic-Kustrin S; Kettle C; Morton DW
    Biomed Pharmacother; 2018 Oct; 106():553-565. PubMed ID: 29990843
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Advanced Structure-activity Relationships Applied to Mentha spicata L. Subsp. spicata Essential Oil Compounds as AChE and NMDA Ligands, in Comparison with Donepezil, Galantamine and Memantine - New Approach in Brain Disorders Pharmacology.
    Avram S; Mernea M; Bagci E; Hritcu L; Borcan LC; Mihailescu DF
    CNS Neurol Disord Drug Targets; 2017; 16(7):800-811. PubMed ID: 28088901
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Potential therapeutic agents against Alzheimer's disease from natural sources.
    Park SY
    Arch Pharm Res; 2010 Oct; 33(10):1589-609. PubMed ID: 21052936
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cholinesterase inhibitors used in the treatment of Alzheimer's disease: the relationship between pharmacological effects and clinical efficacy.
    Wilkinson DG; Francis PT; Schwam E; Payne-Parrish J
    Drugs Aging; 2004; 21(7):453-78. PubMed ID: 15132713
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ginkgo biloba Extract (EGb761), Cholinesterase Inhibitors, and Memantine for the Treatment of Mild-to-Moderate Alzheimer's Disease: A Network Meta-Analysis.
    Thancharoen O; Limwattananon C; Waleekhachonloet O; Rattanachotphanit T; Limwattananon P; Limpawattana P
    Drugs Aging; 2019 May; 36(5):435-452. PubMed ID: 30937879
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Further SAR studies on natural template based neuroprotective molecules for the treatment of Alzheimer's disease.
    Singh YP; Shankar G; Jahan S; Singh G; Kumar N; Barik A; Upadhyay P; Singh L; Kamble K; Singh GK; Tiwari S; Garg P; Gupta S; Modi G
    Bioorg Med Chem; 2021 Sep; 46():116385. PubMed ID: 34481338
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacotherapeutic approaches to the treatment of Alzheimer's disease.
    Standridge JB
    Clin Ther; 2004 May; 26(5):615-30. PubMed ID: 15220008
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cholinesterase inhibitors for Alzheimer's disease.
    Birks J
    Cochrane Database Syst Rev; 2006 Jan; 2006(1):CD005593. PubMed ID: 16437532
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The clinical and cost-effectiveness of donepezil, rivastigmine, galantamine and memantine for Alzheimer's disease.
    Loveman E; Green C; Kirby J; Takeda A; Picot J; Payne E; Clegg A
    Health Technol Assess; 2006 Jan; 10(1):iii-iv, ix-xi, 1-160. PubMed ID: 16409879
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Potential Therapeutic Approaches to Alzheimer's Disease By Bioinformatics, Cheminformatics And Predicted Adme-Tox Tools.
    Avram S; Mernea M; Limban C; Borcan F; Chifiriuc C
    Curr Neuropharmacol; 2020; 18(8):696-719. PubMed ID: 31885353
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.